Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
1(50.0%)
N/A
1(50.0%)
2Total
Early Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT03090009Early Phase 1Unknown

Microbiome Shift in Peri-mucositis by Anti-inflammatory Drugs

Role: lead

NCT02010307Not ApplicableUnknown

Polymorphonuclear Cells' Sensitivity to Aggregatibacter Actinomycetemcomitans Bacteria in Patients With Aggressive Periodontitis

Role: lead

All 2 trials loaded